News

The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.

GBI Enhances Its Position in Radiopharmaceutical Manufacturing Through the Acquisition of a New Contract for Commercial Manufacturing

Wednesday, January 10, 2024

GBI BioManufacturing formerly recognized as Goodwin Biotechnology is excited to announce the completion of its second master supply agreement for the commercialization of a radioimmunoconjugate product

Constant Therapeutics Commences Phase 2 Clinical Trial for TXA127 in Ischemic Stroke Recovery with First Patient Dosed

Wednesday, January 10, 2024

Constant Therapeutics LLC a biopharmaceutical firm specializing in treatments affecting the Alternative ReninAngiotensin System has commenced its phase clinical trial for TXA This is the companys

Medison Pharma and Regeneron Pharmaceuticals Have Signed an Agreement for the Commercialization of Libtayo® (Cemiplimab) in Various Countries

Tuesday, January 09, 2024

Medison Pharma a global pharmaceutical company dedicated to providing access to innovative therapies internationally recently announced an exclusive multinational agreement with Regeneron Ireland DAC

Debiopharm Extends Collaboration with SunRock Biopharma for Antibody-Drug Conjugates Targeting HER3 in EGFR-Mutated Cancers

Tuesday, January 09, 2024

Debiopharm a Swiss biopharmaceutical company specializing in cancer and infectious disease treatments has secured an option for an exclusive licensing agreement with SunRock Biopharma SunRock Biopharma

Aegle Therapeutics Corp. Shares Positive Outcomes for the First Participant in Phase 1/2a Clinical Trial Treated with AGLE-102™, a Novel Extracellular Vesicle Therapy

Tuesday, January 09, 2024

Aegle Therapeutics Corp has revealed positive results from the initial week evaluation of the first participant in its Phase a clinical trial for AGLE an innovative extracellular vesicle

Orion and Glykos Announce a Collaborative Research Initiative and Licensing Agreement Aimed at Advancing the Development of Next-generation ADCs

Monday, January 08, 2024

Orion Corporation and Glykos Finland Oy have jointly announced a research collaboration and licensing agreement for the development of nextgeneration antibodydrug conjugates

Essential Pharma Obtains European Rights to Colobreathe® (Colistimethate Sodium) Through Acquisition From Teva

Monday, January 08, 2024

Essential Pharma an international specialty pharmaceutical group committed to providing sustainable access to lowvolume clinically established pharmaceutical products in key therapeutic areas has successfully concluded the acquisition

Nimbus Therapeutics Unveils Enlargement of Its Immunology Drug Discovery Pipeline

Saturday, January 06, 2024

Nimbus Therapeutics LLC a biotechnology company known for its innovative computational drug discovery engine has announced the expansion and advancement of its pipeline by introducing discovery programs targeting innate immunity pathways

Rivus Pharmaceuticals has successfully concluded the enrollment phase for the Phase 2a HuMAIN Trial of HU6

Saturday, January 06, 2024

Rivus Pharmaceuticals Inc a clinicalstage biopharmaceutical company dedicated to enhancing cardiometabolic health has successfully concluded the enrollment phase for its Phase a HuMAIN trial of HU HU

Anocca Secures GMP Manufacturing License for Advancing Innovative KRAS TCR-T Cell Therapies in Clinical Development

Friday, January 05, 2024

Anocca AB a prominent company specializing in T cell receptorengineered T cell therapies has announced that it has received a certificate of good manufacturing practice compliance